AR119318A1 - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1Info
- Publication number
- AR119318A1 AR119318A1 ARP200101853A ARP200101853A AR119318A1 AR 119318 A1 AR119318 A1 AR 119318A1 AR P200101853 A ARP200101853 A AR P200101853A AR P200101853 A ARP200101853 A AR P200101853A AR 119318 A1 AR119318 A1 AR 119318A1
- Authority
- AR
- Argentina
- Prior art keywords
- modulator
- positive
- allesteric
- methyl
- tetrahydroisoquinoline derivative
- Prior art date
Links
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a un compuesto de acuerdo con la fórmula (1), que es un modulador alostérico positivo de D1 y, en consecuencia, es beneficioso como agente farmacéutico para el tratamiento de enfermedades en las cuales los receptores D1 juegan un papel. Reivindicación 1: 2-(3,5-dicloro-1-metil-indazol-4-il)-1-[(1S,3R)-3-(hidroximetil)-5-(1-hidroxi-1-metil-etil)-1-metil-3,4-dihidro-1H-isoquinolin-2-il]etenona de la fórmula (1), o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119318A1 true AR119318A1 (es) | 2021-12-09 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101853A AR119318A1 (es) | 2019-07-01 | 2020-06-30 | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220259179A1 (es) |
| EP (1) | EP3993794A1 (es) |
| JP (1) | JP7510444B2 (es) |
| KR (1) | KR20220029686A (es) |
| CN (2) | CN117700395A (es) |
| AR (1) | AR119318A1 (es) |
| AU (1) | AU2020299953A1 (es) |
| BR (1) | BR112021022378A2 (es) |
| CA (1) | CA3139571A1 (es) |
| CL (1) | CL2021002946A1 (es) |
| CO (1) | CO2021018155A2 (es) |
| EC (1) | ECSP21093559A (es) |
| IL (1) | IL289314A (es) |
| MA (1) | MA56440A (es) |
| MX (1) | MX2021015873A (es) |
| PE (1) | PE20221020A1 (es) |
| PH (1) | PH12021552825A1 (es) |
| SA (1) | SA521431279B1 (es) |
| SG (1) | SG11202112537YA (es) |
| WO (1) | WO2021001288A1 (es) |
| ZA (1) | ZA202109193B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023553457A (ja) | 2020-12-18 | 2023-12-21 | ユーシービー バイオファルマ エスアールエル | 非晶質固体分散体 |
| CN116601161A (zh) | 2020-12-18 | 2023-08-15 | Ucb生物制药有限责任公司 | 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羟基甲基)-5-(1-羟基-1-甲基-乙基)-1-甲基-3,4-二氢-1h-异喹啉-2-基]乙酮的前药 |
| PT4263517T (pt) | 2020-12-18 | 2024-12-17 | UCB Biopharma SRL | Um derivado de tetra-hidroisoquinolina como um modulador positivo alostérico de d1 |
| JP2024509272A (ja) * | 2021-03-09 | 2024-02-29 | イーライ リリー アンド カンパニー | パーキンソン病の進行を減速させるためのメビダレン及び他のｄ１ポジティブアロステリック調節因子の使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008109336A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6622299B2 (ja) | 2014-10-08 | 2019-12-18 | ユーシービー バイオファルマ エスピーアールエル | テトラヒドロイソキノリン誘導体 |
| US10370355B2 (en) * | 2016-04-13 | 2019-08-06 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/es unknown
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/pt unknown
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en active Application Filing
- 2020-06-29 AU AU2020299953A patent/AU2020299953A1/en active Pending
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/zh active Pending
- 2020-06-29 US US17/621,851 patent/US20220259179A1/en active Pending
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/ko active Pending
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 PH PH1/2021/552825A patent/PH12021552825A1/en unknown
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/es unknown
- 2020-06-29 JP JP2021577411A patent/JP7510444B2/ja active Active
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 MA MA056440A patent/MA56440A/fr unknown
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/zh active Active
- 2020-06-30 AR ARP200101853A patent/AR119318A1/es unknown
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/es unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-23 IL IL289314A patent/IL289314A/en unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/es unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/es unknown
- 2021-12-30 SA SA521431279A patent/SA521431279B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113993857B (zh) | 2024-01-02 |
| BR112021022378A2 (pt) | 2022-03-08 |
| CN117700395A (zh) | 2024-03-15 |
| MA56440A (fr) | 2022-05-11 |
| JP7510444B2 (ja) | 2024-07-03 |
| JP2022539152A (ja) | 2022-09-07 |
| SG11202112537YA (en) | 2021-12-30 |
| CA3139571A1 (en) | 2021-01-07 |
| TW202115010A (zh) | 2021-04-16 |
| PE20221020A1 (es) | 2022-06-16 |
| PH12021552825A1 (en) | 2022-10-03 |
| US20220259179A1 (en) | 2022-08-18 |
| AU2020299953A1 (en) | 2022-01-06 |
| CL2021002946A1 (es) | 2022-07-15 |
| MX2021015873A (es) | 2022-02-03 |
| IL289314A (en) | 2022-02-01 |
| CO2021018155A2 (es) | 2022-01-17 |
| ECSP21093559A (es) | 2022-02-25 |
| EP3993794A1 (en) | 2022-05-11 |
| KR20220029686A (ko) | 2022-03-08 |
| WO2021001288A9 (en) | 2021-09-02 |
| SA521431279B1 (ar) | 2024-01-09 |
| ZA202109193B (en) | 2023-11-29 |
| CN113993857A (zh) | 2022-01-28 |
| WO2021001288A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| AR126052A1 (es) | Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos | |
| MX2020004667A (es) | Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas. | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. | |
| BR112019006937A2 (pt) | Composição farmacêutica, composto, forma cristalina do composto, agentes para reduzir sulfato de indoxila no sangue, para prevenir ou tratar uma doença causada por um aumento de sulfato de indoxila no sangue, para retardar a transição para terapia desubstituição renal e para suprimir o agravamento da função renal remanescente em um paciente após transição para terapia de substituição renal, uso do composto, e, métodos para reduzir sulfato de indoxila no sangue e para prevenir ou tratar uma doença | |
| PE20240632A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1 | |
| BR112022007543A2 (pt) | Derivados de tiofeno como inibidores de xantina oxidase e aplicação dos mesmos | |
| AR120158A2 (es) | Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue | |
| UY38072A (es) | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos | |
| CO2023012711A2 (es) | Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de nr2b | |
| EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
| AR117270A1 (es) | 3,3-difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que comprenden lo mismo | |
| AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 |